By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Miscellaneous antihyperlipidemic agents > Lomitapide > Lomitapide Side Effects
Miscellaneous antihyperlipidemic agents

Lomitapide Side Effects

Summary

Commonly reported side effects of lomitapide include: increased serum alanine aminotransferase, increased serum aspartate aminotransferase, abdominal distention, abdominal distress, abdominal pain, constipation, diarrhea, dyspepsia, fever, nausea, vomiting, and flatulence. Continue reading for a comprehensive list of adverse effects.

Applies to lomitapide: oral capsule.

Warning

Oral route (Capsule)

Lomitapide mesylate can cause elevations in transaminases. Measure ALT, AST, alkaline phosphatase, and total bilirubin before initiating treatment and then ALT and AST regularly as recommended. During treatment, adjust the dose of lomitapide mesylate if the ALT or AST is 3 times the ULN or greater. Discontinue lomitapide mesylate for clinically significant liver toxicity. Lomitapide mesylate increases hepatic fat (hepatic steatosis) with or without concomitant increases in transaminases. Hepatic steatosis associated with lomitapide mesylate may be a risk factor for progressive liver disease, including steatohepatitis and cirrhosis. Because of the risk of hepatotoxicity, lomitapide mesylate is available only through a restricted program called the Juxtapid® REMS Program. Prescribe lomitapide mesylate only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia (HoFH). The safety and effectiveness of lomitapide mesylate have not been established in patients with hypercholesterolemia who do not have HoFH.

Serious side effects of Lomitapide

Along with its needed effects, lomitapide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking lomitapide:

More common

  • Arm, back, or jaw pain
  • chest pain or discomfort
  • chest tightness or heaviness
  • dark urine
  • fast, irregular, pounding, or racing heartbeat or pulse
  • fever
  • light-colored stools
  • loss of appetite
  • nausea and vomiting
  • sweating
  • trouble breathing
  • unusual tiredness or weakness
  • upper right abdominal or stomach pain
  • yellow eyes and skin

Other side effects of Lomitapide

Some side effects of lomitapide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Acid or sour stomach
  • back pain
  • belching
  • chills
  • constipation
  • cough
  • decreased weight
  • diarrhea
  • dizziness
  • excess air or gas in the stomach or intestines
  • frequent urge to defecate
  • full or bloated feeling
  • general feeling of discomfort or illness
  • headache
  • heartburn
  • indigestion
  • joint pain
  • muscle aches and pains
  • passing gas
  • pressure in the stomach
  • shivering
  • sore throat
  • stomach discomfort, upset, or pain
  • straining while passing stool
  • stuffy or runny nose
  • sweating
  • swelling of the abdominal or stomach area
  • trouble sleeping
  • weakness

Incidence not known

  • Hair loss or thinning of the hair

For Healthcare Professionals

Applies to lomitapide: oral capsule.

Cardiovascular

Very common (10% or more): Chest pain (24%), angina pectoris (10%), palpitations (10%)[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (79%), nausea (65%), dyspepsia (38%), vomiting (34%), abdominal pain (34%), abdominal discomfort (21%), abdominal distention (21%), constipation (21%), flatulence (21%), gastroesophageal reflux disease (10%), defecation urgency ((10%), rectal tenesmus (10%), gastroenteritis (14%)[Ref]

Hepatic

Very common (10% or more): Increased ALT (17%), at least one elevation in ALT and/or AST greater than or equal to 3 times ULN (29%), hepatic steatosis: of 23 patients in a study for 78 weeks, 18 (78%) exhibited an increase in hepatic fat greater than 5% and 3 (13%) exhibited an increase greater than 20%[Ref]

Immunologic

Very common (10% or more): Influenza (21%)[Ref]

Metabolic

Very common (10% or more): Weight loss (24%)[Ref]

Nervous system

Very common (10% or more): Fatigue (17%), fever (10%), headache (10%), dizziness (10%)[Ref]

Respiratory

Very common (10% or more): Nasopharyngitis (17%), pharyngolaryngeal pain (14%), nasal congestion (10%)[Ref]

Dermatologic

Common (1% to 10%): Ecchymosis, papule, rash erythematous, xanthoma[Ref]

Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by